Scarica l'app Stockscreener
0.1489
1.25%
-0.00303
Precedente Chiudi:
$0.1519
Aprire:
$0.148
Volume 24 ore:
370.81K
Relative Volume:
0.37
Capitalizzazione di mercato:
$6.04M
Reddito:
-
Utile/perdita netta:
$-51.06M
Rapporto P/E:
-0.1079
EPS:
-1.38
Flusso di cassa netto:
$-40.03M
1 W Prestazione:
-5.00%
1M Prestazione:
-37.50%
6M Prestazione:
-81.25%
1 anno Prestazione:
-72.44%
Intervallo 1D:
$0.1445
$0.1549
Intervallo di 1 settimana:
$0.1315
$0.1579
Portata 52W:
$0.1315
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Nome
Viracta Therapeutics Inc
Settore
Industria
Telefono
858-400-8470
Indirizzo
2533 S COAST HWY 101, CARDIFF
Confronta VIRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VIRX | 0.1507 | 6.04M | 0 | -51.06M | -40.03M | -1.38 |
| VRTX | 448.50 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.48 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.11 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Iniziato | SVB Leerink | Outperform |
| 2021-03-25 | Iniziato | Evercore ISI | Outperform |
Viracta Therapeutics Inc Borsa (VIRX) Ultime notizie
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK
Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com
Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times
Viracta Therapeutics Announces Reprioritization of - GlobeNewswire
Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan
Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance
T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic
Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR
Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India
Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech
Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Perhaps timely catching Viracta Therapeutics Inc (VIRX) would be a good idea - SETE News
Biopharma Layoff Tracker 2024: Lykos, Galera, Grail and More Cut Staff - BioSpace
Examining Viracta Therapeutics Inc (VIRX) stock is warranted - US Post News
Viracta Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Stock Surge: Viracta Therapeutics Inc (VIRX) Closes at 0.31, Marking a -11.76 Increase/Decrease - The Dwinnex
Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Downgraded by SVB Leerink to “Market Perform” - Defense World
What is Viracta Therapeutics Inc (VIRX) Stock Return on Shareholders’ Capital? - SETE News
Viracta Therapeutics stock PT lowered by RBC amid pipeline strategy shift - Investing.com Canada
Viracta reports progress in PTCL treatment trial By Investing.com - Investing.com Australia
Sunesis: Q2 Earnings Snapshot - San Antonio Express-News
Viracta reports progress in PTCL treatment trial - Investing.com
A Closer Look at Viracta Therapeutics Inc (VIRX) Stock Gains - The InvestChronicle
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024 - MSN
Viracta Therapeutics Inc Azioni (VIRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viracta Therapeutics Inc Azioni (VIRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pomerantz Roger | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
117,444 |
| Pomerantz Roger | Director |
May 25 '24 |
Option Exercise |
0.00 |
9,035 |
0 |
108,410 |
| ROYSTON IVOR | Director |
May 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
789,303 |
| ROYSTON IVOR | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
764,084 |
| Pomerantz Roger | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
99,375 |
| Chevallard Daniel R. | CFO and COO |
Feb 25 '24 |
Option Exercise |
0.00 |
6,889 |
0 |
105,711 |
| Chevallard Daniel R. | CFO and COO |
Feb 27 '24 |
Sale |
0.73 |
3,405 |
2,493 |
102,306 |
| Rothera Mark | President and CEO |
Nov 30 '23 |
Buy |
0.49 |
52,094 |
25,734 |
52,094 |
| Rothera Mark | President and CEO |
Dec 01 '23 |
Buy |
0.49 |
47,906 |
23,627 |
100,000 |
| Chevallard Daniel R. | CFO and COO |
Nov 25 '23 |
Option Exercise |
0.00 |
6,889 |
0 |
102,542 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):